Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BLIS TechnologiesNZSE:BLT +5.88% Receivables Turnover is 3.65 as of Mar. 2026. The stock has 4 warning signs investors should review. Among 841 Biotechnology companies, BLIS Technologies ranks better than 74.08% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. BLIS Technologies's Revenue for the
six
months ended in Mar. 2026 was NZ$6.23 Mil. BLIS Technologies's average Accounts Receivable for the
six
months ended in Mar. 2026 was NZ$1.71 Mil.
Hence, BLIS Technologies's Receivables Turnover for the
six
months ended in Mar. 2026 was 3.65.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
BLIS Technologies Receivables Turnover Related Terms
BLIS Technologies Receivables Turnover Historical Data
* Premium members only.
The historical data trend for BLIS Technologies's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:BLT vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, BLIS Technologies's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLIS Technologies Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLIS Technologies's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where BLIS Technologies's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLIS Technologies (NZSE:BLT) has a Receivables Turnover of 3.65 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BLIS Technologies and its competitors. According to the industry distribution chart, BLIS Technologies ranks #218 out of 841 companies in the Biotechnology industry, placing it in the top 25.9%.
Is BLIS Technologies' Receivables Turnover too high?
BLIS Technologies' current Receivables Turnover is 3.65. The Biotechnology industry median Receivables Turnover is 5.28. BLIS Technologies' value of 3.65 is 30.9% below this industry median. Based on the distribution chart, BLIS Technologies ranks #218 out of 841 companies in the Biotechnology industry, which is above the industry midpoint.
How does BLIS Technologies' Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BLIS Technologies ranks #218 out of 841 companies for Receivables Turnover. This puts BLIS Technologies in the upper half of its industry. The industry median Receivables Turnover is 5.28. BLIS Technologies' value of 3.65 is 30.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BLIS Technologies's current Receivables Turnover of 3.65 is 30.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BLIS Technologies and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLIS Technologies's current Receivables Turnover is 3.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLIS Technologies stock overvalued right now?
Based on GuruFocus' analysis, BLIS Technologies (NZSE:BLT) is currently considered Modestly Undervalued. The stock's GF Value™ is NZ$0.02, compared to a current price of NZ$0.02 — trading 10% below its estimated fair value. The current Receivables Turnover is 3.65 and 30.9% below the Biotechnology industry median of 5.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For BLIS Technologies (NZSE:BLT), the current Receivables Turnover is 3.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18, which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from North America. The company also generates a small portion of revenue from Non-core business, which includes grants and interest revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:BLT has been successfully added to your 
